AstraZeneca Investor Day Presentation Deck

6 Comprehensive portfolio to combat cancer DENHERTUⓇ fam-trastuzumab deruxtecan-nxki 20 mg/mL INJECTION FOR INTRAVENOUS USE SIMFINZIⓇ durvalumab Injection for Intravenous Use 50 mg/mL Source: AstraZeneca. Lynparza™ olaparib TAGRISSOⓇ osimertinib CALQUENCE (acalabrutinib) 100 mg capsules Redirect local immunity Awaken dormant immune cells Infuse with engineered T cells Build synthetic immunity Cell therapy Targeted delivery of medicines that recruit immunity Build on PDx Overcome immune suppression Diverse pipeline with potential for orthogonal combinations Oncolytic virus Immune engagers Activate immune system Microenvironment Immuno-oncology "Ignore axis" "Defend axis" Tumour drivers and resistance Direct killing Tumour DNA damage response Oncogenic truncal drivers and mechanisms of resistance Synthetic lethality exploiting impaired DNA damage response Antibody drug conjugates Radioimmuno- conjugates Nanomedicines Replacing standard of care (i.e., chemo) with targeted delivery of toxic molecules Epigenetics Reprogramming tumour cells

View entire presentation